RVX Share Price

Open 1.97 Change Price %
High 1.97 1 Day -0.03 -1.50
Low 1.96 1 Week -0.03 -1.50
Close 1.97 1 Month -0.08 -3.90
Volume 2900 1 Year 0.62 45.93
52 Week High 2.47
52 Week Low 1.10
RVX Important Levels
Resistance 2 1.98
Resistance 1 1.98
Pivot 1.97
Support 1 1.96
Support 2 1.96
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
OGC 4.33 0.23%
OGC 4.33 0.23%
OGC 4.33 0.23%
SC 60.83 -0.44%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
PWC 0.10 25.00%
PWC 0.10 25.00%
CUM 0.90 13.92%
CUM 0.90 13.92%
ETG 0.62 12.73%
ETG 0.62 12.73%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
NKO 0.07 -12.50%
NKO 0.07 -12.50%
NKO 0.07 -12.50%
ANX 0.07 -12.50%
ANX 0.07 -12.50%
DNT 0.08 -11.11%
CTU-A 0.19 -9.52%
FTP 6.54 -8.15%
FTP 6.54 -8.15%
More..

Resverlogix Corp (TSE: RVX)

RVX Technical Analysis 2
As on 19th May 2017 RVX Share Price closed @ 1.97 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.75 & Strong Sell for SHORT-TERM with Stoploss of 2.13 we also expect STOCK to react on Following IMPORTANT LEVELS.
RVX Target for May
1st Target up-side 2.3
2nd Target up-side 2.52
3rd Target up-side 2.74
1st Target down-side 1.68
2nd Target down-side 1.46
3rd Target down-side 1.24
RVX Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.resverlogix.com
RVX Address
RVX
279 Midpark Way S.E.
Suite 202
Calgary, AB T2X 1M2
Canada
Phone: 403-254-9252
Fax: 403-256-8495
Interactive Technical Analysis Chart Resverlogix Corp ( RVX TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Resverlogix Corp
RVX Business Profile
Resverlogix Corp., a clinical stage cardiovascular company, develops compounds, which include a therapeutic increase in Apolipoprotein A-I. It primarily develops RVX-208, a small molecule that has completed a Phase IIb clinical trial SUSTAIN and is undergoing a second Phase IIb trial ASSURE for the treatment of atherosclerosis and other chronic diseases, such as neurodegenerative disorders, diabetes mellitus, and Alzheimer's disease. The company is headquartered in Calgary, Canada.